| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Department of Veterinary Biosciences, 2 Division of Human Cancer Genetics, 3 College of Medicine and Public Health, 4 Division of Hematology-Oncology, Comprehensive Cancer Center and The Ohio State University, Columbus, Ohio, and 5 Division of Hematology/Oncology, Department of Medicine, University of California, San Diego, California
CpG island methylation is an epigenetic alteration that contributes to tumorigenesis by transcriptional inactivation of genes. Little is known about the overall levels of CpG island methylation in chronic lymphocytic leukemia (CLL). To provide a baseline estimate of global aberrant methylation and identify target sequences for additional investigation, we performed Restriction Landmark Genomic Scanning on 10 CLL samples. Two methylation-sensitive landmark enzymes were used (NotI and AscI), allowing assessment of over 3000 CpG islands in each sample. Tumor-derived Restriction Landmark Genomic Scanning profiles were compared with profiles from CD19-selected B cells from normal volunteers and matched normal neutrophils from 4 CLL patients. We found 2.58.1% (mean 4.8%) of the CpG islands in CLL samples were aberrantly methylated compared with controls, and the methylation events had a nonrandom distribution (P < 0.0001). Furthermore, we identified 193 aberrantly methylated sequences, of which 93% have CpG island characteristics and 90% have homology to genes or expressed sequences. One such gene, the G protein-coupled metabotropic glutamate receptor 7 (GRM7), possibly inhibits cyclic AMP signaling in the induction of apoptosis. Bisulfite sequencing of GRM7 confirmed extensive CpG island methylation, and treatment with 5-aza-2'-deoxycytidine (decitabine) resulted in up-regulated expression of several genes in vitro with concurrent cellular depletion of DNMT1 protein. Our dual-enzyme global methylation study shows that CLL is characterized by widespread nonrandom CpG island methylation similar to other tumors and provides a panel of novel methylation targets that can be used in larger studies designed to assess impact on disease progression and survival.
This article has been cited by other articles:
![]() |
S. Garaud, C. Le Dantec, C. Berthou, P. M. Lydyard, P. Youinou, and Y. Renaudineau Selection of the Alternative Exon 1 from the cd5 Gene Down-Regulates Membrane Level of the Protein in B Lymphocytes J. Immunol., August 1, 2008; 181(3): 2010 - 2018. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Kim, K. Yamashita, Y. K. Chae, Y. Tokumaru, X. Chang, M. Zahurak, M. Osada, H. L. Park, A. Chuang, J. A. Califano, et al. A Promoter Methylation Pattern in the N-Methyl-D-Aspartate Receptor 2B Gene Predicts Poor Prognosis in Esophageal Squamous Cell Carcinoma Clin. Cancer Res., November 15, 2007; 13(22): 6658 - 6665. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Motiwala, S. Majumder, H. Kutay, D. S. Smith, D. S. Neuberg, D. M. Lucas, J. C. Byrd, M. Grever, and S. T. Jacob Methylation and Silencing of Protein Tyrosine Phosphatase Receptor Type O in Chronic Lymphocytic Leukemia Clin. Cancer Res., June 1, 2007; 13(11): 3174 - 3181. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Allegrucci, Y.-Z. Wu, A. Thurston, C. N. Denning, H. Priddle, C. L. Mummery, D. Ward-van Oostwaard, P. W. Andrews, M. Stojkovic, N. Smith, et al. Restriction landmark genome scanning identifies culture-induced DNA methylation instability in the human embryonic stem cell epigenome Hum. Mol. Genet., May 15, 2007; 16(10): 1253 - 1268. [Abstract] [Full Text] [PDF] |
||||
![]() |
C S Chim, T K Fung, K F Wong, J S Lau, M Law, and R Liang Methylation of INK4 and CIP/KIP families of cyclin-dependent kinase inhibitor in chronic lymphocytic leukaemia in Chinese patients J. Clin. Pathol., September 1, 2006; 59(9): 921 - 926. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Zhang, H. Y. Wang, A. Woetmann, P. N. Raghunath, N. Odum, and M. A. Wasik STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes Blood, August 1, 2006; 108(3): 1058 - 1064. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Kim, K. Yamashita, J. H. Baek, H. L. Park, A. L. Carvalho, M. Osada, M. O. Hoque, S. Upadhyay, M. Mori, C. Moon, et al. N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res., April 1, 2006; 66(7): 3409 - 3418. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Yuan, F. Haghighi, S. White, R. Costa, J. McMinn, K. Chun, M. Minden, and B. Tycko A single nucleotide polymorphism chip-based method for combined genetic and epigenetic profiling: validation in decitabine therapy and tumor/normal comparisons. Cancer Res., April 1, 2006; 66(7): 3443 - 3451. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-H. Liu, A. Raval, S.-S. Chen, J. J. Matkovic, J. C. Byrd, and C. Plass CpG Island Methylation and Expression of the Secreted Frizzled-Related Protein Gene Family in Chronic Lymphocytic Leukemia Cancer Res., January 15, 2006; 66(2): 653 - 658. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Nishiyama, L. Qi, M. Lacey, and M. Ehrlich Both Hypomethylation and Hypermethylation in a 0.2-kb Region of a DNA Repeat in Cancer Mol. Cancer Res., November 1, 2005; 3(11): 617 - 626. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Raval, D. M. Lucas, J. J. Matkovic, K. L. Bennett, S. Liyanarachchi, D. C. Young, L. Rassenti, T. J. Kipps, M. R. Grever, J. C. Byrd, et al. TWIST2 Demonstrates Differential Methylation in Immunoglobulin Variable Heavy Chain Mutated and Unmutated Chronic Lymphocytic Leukemia J. Clin. Oncol., June 10, 2005; 23(17): 3877 - 3885. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Liu, T. Shen, L. Huynh, M. I. Klisovic, L. J. Rush, J. L. Ford, J. Yu, B. Becknell, Y. Li, C. Liu, et al. Interplay of RUNX1/MTG8 and DNA Methyltransferase 1 in Acute Myeloid Leukemia Cancer Res., February 15, 2005; 65(4): 1277 - 1284. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Weber, M. A. Aldred, C. D. Morrison, C. Plass, A. Frilling, C. E. Broelsch, K. A. Waite, and C. Eng Silencing of the Maternally Imprinted Tumor Suppressor ARHI Contributes to Follicular Thyroid Carcinogenesis J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1149 - 1155. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Byrd, G. Marcucci, M. R. Parthun, J. J. Xiao, R. B. Klisovic, M. Moran, T. S. Lin, S. Liu, A. R. Sklenar, M. E. Davis, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia Blood, February 1, 2005; 105(3): 959 - 967. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |